Predictors for survival in patients with bone metastasis of small cell lung cancer
A population-based study

MingFeng Xue, MD*†, Gang Chen, MD, XingGuang Chen, MD, JunYu Hu, MD

Abstract
The objective of the current study is to analyze the clinical and demographic characteristics of patients with bone metastasis of small cell lung cancer (SCLC) and explore their survival predictors.

We retrospectively extracted patients with bone metastasis of SCLC from the Surveillance, Epidemiology, and End Results database. We applied Cox regression analyses to identify independent survival predictor of overall survival (OS) and cancer-specific survival (CSS). Only significant predictors from univariable analysis were included for multivariable Cox analysis. Kaplan–Meier method was used to evaluate survival differences between groups by the log–rank test.

A total of 5,120 patients with bone metastasis of SCLC were identified and included for survival analysis. The 1-year OS and CSS rates of bone metastasis of SCLC were 19.8% and 21.4%, respectively. On multivariable analysis, gender, age, radiotherapy, chemotherapy, liver metastasis, brain metastasis, insurance status, and marital status independently predicted OS and CSS. There was no significant difference of OS and CSS in terms of race and tumor size.

Independent predictors of survival were identified among patients with bone metastasis of SCLC, which could be valuable to clinicians in treatment decision. Patients with bone metastasis of SCLC may benefit from radiotherapy and chemotherapy.

Abbreviations: CSS = cancer-specific survival, NSCLC = nonsmall cell lung cancer, OS = overall survival, SCLC = small cell lung cancer, SEER = Surveillance, Epidemiology, and End Results.

Keywords: bone metastasis, characteristics, prognosis, small cell lung cancer, survival predictor

1. Introduction
Small cell lung cancer (SCLC) is a highly invasive neuroendocrine tumor, accounting for about 10% to 15% of all lung cancer patients.[1] Bone, as one of the common metastatic sites of SCLC,[2] is also one of the main reasons for treatment failure.[3,4]

Among all lung cancer types, SCLC has the worst prognosis, which has not changed much in the past few decades.[5,6] Additionally, the prognosis of patients with bone metastasis of SCLC, was worse than that of nonsmall cell lung cancer (NSCLC) type.[7] To date, chemotherapy and radiotherapy are still the main treatments for SCLC, which are beneficial for prolonging survival.[8,9] Surgery for SCLC remains controversial and is only considered for patients with early stage SCLC.[10] We can’t help wondering whether these treatments will also prolong the prognosis of patients with bone metastasis of SCLC. Currently, evidence on appropriate treatments for them is lacking.

Rational therapeutic strategies of bone metastasis of SCLC depend on the patients’ prognosis. At present, there are few studies on exploring prognostic risk factors among patients with bone metastasis of SCLC. Therefore, we sought to further determine the clinical predictors of survival among patients with bone metastasis of SCLC, which may result in treatment improvement. We applied the Surveillace, Epidemiology, and End Results (SEER) database in the present study, due to its popularity in survival analysis of cancer patients.

2. Methods
2.1. Study population
In this retrospective study, we extracted bone metastasis of SCLC cases from the SEER database using SEER* Stat Version 8.3.6 (https://seer.cancer.gov/). As a large-scale, population-based database, the SEER represents approximately one-third of the US population and covers 20 geographic areas in the US, which provides a free tool for clinical study of malignant tumors. This database does not contain any patient identification information and approval by institutional research ethics committee was not applicable to this study.
According to the International Classification of Diseases for Oncology, Third edition, we identified primary SCLC by histological subtype codes: 8002, 8041, 8043, 8144, 8145. The database only records bone metastasis information after 2010, so we only included patients diagnosed with SCLC with bone metastasis from 2010 to 2016. Additionally, patients who lacked information about pathological diagnosis, tumor size, treatment, survival time, and metastatic status were excluded. Clinical and pathological data were retrieved, including race, gender, continuous age, tumor size, radiotherapy, chemotherapy, metastatic status, survival time, insurance status, and marital status. In our study, radiotherapy refers to the local treatment of primary SCLC.

### 2.2. Statistical analyses

We performed all statistical analyses by using SPSS v22.0 (Chicago, IL). Cancer-specific survival (CSS) was defined as the time from diagnosis till death due to SCLC. We performed Cox regression analysis to identify independent survival predictor of overall survival (OS) and CSS. Only significant predictors from univariable analysis were included for multivariable Cox analysis. During Cox regression analyses, we also calculated hazard ratios along with 95% confidence interval to show the impact of predictors on survival. Kaplan–Meier method was used to evaluate survival differences between groups by the log–rank test. Variables with bilateral \( P < .05 \) were considered to be statistically significant.

### 3. Results

#### 3.1. Baseline characteristics

The entire cohort comprised 5120 patients with bone metastasis of SCLC. Clinical and demographic characteristics for these patients were listed in Table 1. Of these patients, more than 3 quarters of patients (88.9%) were white and over half of patients (54.7%) were male. Approximately 21.9% of the cases were aged <60 years, 37.9% were 60 to 69 years, 30.1% were 70 to 79 years and 10.2% were ≥80 years. Tumor size was also classified into 4 categories, including <3 cm (n = 1208, 23.6%), 3 to 5.9 cm (n = 1946, 38.0%), 6 to 8.9 cm (n = 1268, 24.8%), and ≥9 cm (n = 698, 13.6%). Radiotherapy was performed for 2092 (40.9%), and chemotherapy was performed for 3768 (73.6%). Brain metastasis accounted for 20.2%, and liver metastasis accounted for 56.2%. Most patients (82.1%) were insured and over half of the patients (53.8%) were married. In all patients, the 1-year OS and CSS rates were 19.8% and 21.4%, respectively.

#### 3.2. Univariable Cox regression analysis

Univariable Cox regression analysis could be seen in Table 2. On univariable analysis, female, younger age, radiotherapy, chemother-

### Table 1

**Baseline characteristics of 5120 patients with bone metastasis of small cell lung cancer.**

| Race       | White   | 4550 (88.9%) |
|------------|---------|--------------|
|            | Black   | 387 (7.6%)   |
|            | Others  | 183 (3.6%)   |
| Gender     | Female  | 2319 (45.3%) |
|            | Male    | 2801 (54.7%) |
| Age (yr)   | <60     | 1122 (21.9%) |
|            | 60 to 69| 1938 (37.9%) |
|            | 70 to 79| 1539 (30.1%) |
|            | ≥80     | 521 (10.2%)  |
| Tumor size (cm) | <3     | 1208 (23.6%) |
|            | 3 to 5.9| 1946 (38.0%) |
|            | 6 to 8.9| 1268 (24.8%) |
|            | ≥9      | 698 (13.6%)  |
| Radiotherapy | Yes    | 2092 (40.9%) |
|            | No      | 3028 (59.1%) |
| Chemotherapy | Yes    | 3768 (73.6%) |
|            | No      | 1352 (26.4%) |
| Brain metastasis | No     | 4087 (79.8%) |
|            | Yes     | 1033 (20.2%) |
| Liver metastasis | No     | 2241 (43.8%) |
|            | Yes     | 2679 (56.2%) |
| Insurance status | Insured | 4201 (82.1%) |
|            | Any Medicaid | 770 (15.0%) |
|            | Uninsured | 149 (2.9%)  |
| Marital status | Married  | 2755 (53.8%) |
|            | Others  | 2365 (46.2%) |

### Table 2

**Univariate Cox analysis of variables in patients with bone metastasis of small cell lung cancer.**

| Variable          | OS HR (95% CI) | P     | CSS HR (95% CI) | P     |
|-------------------|----------------|-------|-----------------|-------|
| Race              |                |       |                 |       |
| White             | 1              |       |                 |       |
| Black             | 0.946 (0.849–1.055) | .322 | 0.955 (0.844–1.081) | .467 |
| Others            | 0.899 (0.769–1.052) | .185 | 0.892 (0.747–1.066) | .208 |
| Gender            |                |       |                 |       |
| Female            | 1              |       |                 |       |
| Male              | 1.097 (1.035–1.162) | .002 | 1.117 (1.046–1.193) | .001 |
| Age (yr)          |                |       |                 |       |
| <60               | 1              |       |                 |       |
| 60 to 69          | 1.104 (1.021–1.194) | .013 | 1.123 (1.031–1.223) | .008 |
| 70 to 79          | 1.322 (1.219–1.434) | <.001 | 1.295 (1.185–1.419) | <.001 |
| ≥80               | 1.771 (1.587–1.975) | <.001 | 1.656 (1.455–1.885) | <.001 |
| Tumor size (cm)   |                |       |                 |       |
| <3                | 1              |       |                 |       |
| 3 to 5.9          | 1.034 (0.958–1.115) | .392 | 1.043 (0.966–1.138) | .344 |
| 6 to 8.9          | 1.012 (0.931–1.100) | .782 | 1.020 (0.927–1.122) | .687 |
| ≥9                | 1.051 (0.953–1.160) | .321 | 1.067 (0.954–1.193) | .257 |
| Radiotherapy      |                |       |                 |       |
| Yes               | 1              |       |                 |       |
| No                | 1.417 (1.336–1.504) | <.001 | 1.384 (1.295–1.480) | <.001 |
| Chemotherapy      |                |       |                 |       |
| Yes               | 1              |       |                 |       |
| No                | 3.722 (3.475–3.985) | <.001 | 3.889 (3.597–4.205) | <.001 |
| Brain metastasis  |                |       |                 |       |
| No                | 1              |       |                 |       |
| Yes               | 1.207 (1.124–1.297) | <.001 | 1.274 (1.176–1.381) | <.001 |
| Liver metastasis  |                |       |                 |       |
| No                | 1              |       |                 |       |
| Yes               | 1.372 (1.294–1.455) | <.001 | 1.411 (1.320–1.509) | <.001 |
| Insurance status  |                |       |                 |       |
| Insured           | 1              |       |                 |       |
| Any Medicaid      | 1.044 (0.963–1.131) | .298 | 1.052 (0.961–1.151) | .272 |
| Uninsured         | 1.304 (1.102–1.544) | .002 | 1.332 (1.112–1.596) | .002 |
| Marital status    |                |       |                 |       |
| Married           | 1              |       |                 |       |
| Others            | 1.157 (1.083–1.235) | <.001 | 1.157 (1.083–1.235) | <.001 |

CI = confidence interval, CSS = cancer-specific survival, HR = hazard ratio, OS = overall survival.
therapy, no brain and liver metastasis, insured status, and married status were significant predictors for increased OS and CSS. Race and tumor size had no obvious effect on survival time. Patients who received radiotherapy had better OS and CSS than those who did not receive radiotherapy (Fig. 1A and 1B, \( P < .001 \)). Similarly, patients treated by chemotherapy experienced significantly prolonged OS and CSS than those who did not receive chemotherapy (Fig. 1C and 1D, \( P < .001 \)). The survival curves showed that patients with brain or liver metastasis experienced significantly poorer prognosis (Fig. 2, \( P < .001 \)).

### 3.3 Multivariable Cox regression analysis

Table 3 showed the results of multivariable Cox regression analysis. On multivariable analysis, gender, age, radiotherapy, chemotherapy, liver metastasis, brain metastasis, insurance status, and marital status were significant independent predictors of both OS and CSS.

### 4. Discussion

With the increase in the overall incidence of bone metastasis due to lung cancer, this field has gradually become one of the hotspots of clinical research.\(^{[11]}\) Although there have been many reports on bone metastasis of lung cancer recently, the research population is mainly patients with bone metastasis of NSCLC. SCLC is an aggressive neuroendocrine malignancy prone to metastasis, which is different from NSCLS.\(^{[12]}\) To date, SCLC remains an important challenge for the clinicians. Therefore, it is necessary and crucial to separately explore different subtypes of lung cancer with bone metastasis. In the present study, we first analyzed the
clinical and demographic characteristics of bone metastasis of SCLC based on the SEER database. Furthermore, we determined several independent predictors of survival, in an attempt to make better clinical decisions.

The 1-year OS and CSS rates of bone metastasis of SCLC were 19.8% and 21.4%, respectively, indicating a quite poor prognosis. No difference was observed in OS and CSS by race, which was consistent with a previous study about bone metastasis of all lung cancers.[3] However, some researchers found that white race could predict poor OS and CSS of bone metastasis of NSCLC.[13,14] Our multivariable analysis showed that gender was significantly correlated with OS and CSS, which was congruent with many previous studies.[3,15,16] This study found that older age independently predicted a poorer OS and CSS, which was consistent with others.[3,17,18] There was no difference in OS and CSS by tumor size in our study. However, some researchers reported significant relationships between tumor size and survival in lung cancer with bone metastasis.[3,19] Further research is needed to confirm this finding. Distant metastasis was usually recognized as an important predictor of worse survival of lung cancer.[15,19,20] Our study identified that brain and liver metastasis were independent prognostic factors for bone metastasis of SCLC, suggesting that treating both of these metastases may prolong survival.

Another feature of this study is that marital and insurance status had an impact on the prognosis of SCLC with bone metastasis. Figure 2. Kaplan–Meier method estimated OS and CSS in patients with bone metastasis of small cell lung cancer stratified by distant metastasis. (A) OS stratified by brain metastasis; (B) CSS stratified by brain metastasis; (C) OS stratified by liver metastasis; (D) CSS stratified by liver metastasis. (CSS = cancer-specific survival, OS = overall survival).
metastasis. Similarly, Huang et al[16] reported that marital status was an independent prognostic factor of lung adenocarcinoma with brain metastases. Reddy et al[21] reported that lack of insurance was the strongest predictor of mortality for SCLC with brain metastasis. This suggests that clinicians need to pay attention to the economic level and marital status of patients with advanced cancers.

In terms of treatment methods, radiotherapy and chemotherapy are common treatment methods for SCLC.[22,23] However, few studies have explored whether the above methods are equally effective for SCLC patients with bone metastasis. Radiotherapy is usually considered as a palliative local treatment, mainly used for symptomatic treatment.[24,25] However, this study is the first to find that radiotherapy was one of the important independent risk factors affecting the prognosis of SCLC patients with bone metastasis. Interestingly, of all risk factors, chemotherapy showed the greatest effect on prognosis in patients with bone metastasis of SCLC. Additionally, Cho et al[7] found that surgical treatment for bone metastasis was a positive independent predictor of survival among lung cancer patients. Putatively, treatment of bone metastasis may be helpful in prolonging outcomes in patients with bone metastasis of SCLC.

Although the SEER database contains a large amount of information on lung cancer patients from different regions and provides a useful tool for oncologist, there are several limitations in this study. First, bias may occur due to the retrospective nature of the study. Second, we do not obtain other potential clinical predictors in the SEER database, such as molecular markers and target therapy. Third, the SEER database does not provide detailed bone metastasis information.

### 5. Conclusions

This is the largest study to identify independent prognostic factors for patients with bone metastasis of SCLC. Gender, age, radiotherapy, chemotherapy, liver metastasis, brain metastasis, insurance status, and marital status were recognized as independent survival predictors. Better understandings of these survival predictors in patients with bone metastasis of SCLC could help clinicians with better treatment decision. However, further studies are needed to confirm our findings.

### Acknowledgments

We thank the contribution of the SEER database.

### Author contributions

Conceptualization: Mingfeng Xue.
Data curation: Mingfeng Xue, Gang Chen, XingGuang Chen, JunYu Hu.
Formal analysis: Mingfeng Xue, Gang Chen, XingGuang Chen.
Funding acquisition: Mingfeng Xue.
Investigation: Mingfeng Xue, Gang Chen.
Methodology: Mingfeng Xue, Gang Chen, XingGuang Chen, JunYu Hu.
Project administration: Mingfeng Xue.
Software: Mingfeng Xue, XingGuang Chen, JunYu Hu.
Supervision: Mingfeng Xue.
Writing – original draft: Mingfeng Xue.
Writing – review & editing: Mingfeng Xue.
References

[1] Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539–44.

[2] Lee K, Jung HA, Sun JM, et al. Clinical characteristics and outcomes of non-small cell lung cancer patients with HER2 alterations in Korea. Cancer Res Treat 2020;52:292–300.

[3] Zheng XQ, Huang JF, Lin JL, et al. Incidence, prognostic factors, and a nomogram of lung cancer with bone metastasis at initial diagnosis: a population-based study. Transl Lung Cancer Res 2019;8:367–79.

[4] Cetin K, Christiansen CF, Jacobsen JB, Nørgaard M, Sørensen HT. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer 2014;86:247–54.

[5] Tartarone A, Giordano P, Lerose R, Rodriguez MG, Conca R, Aieta M. Progress and challenges in the treatment of small cell lung cancer. Med Oncol 2017;34:110.

[6] Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther 2017;180:16–23.

[7] Cho YJ, Cho YM, Kim SH, Shin KH, Jung ST, Kim HS. Clinical analysis of patients with skeletal metastasis of lung cancer. BMC Cancer 2019;19:303.

[8] Zhang R, Li P, Li Q, et al. Radiotherapy improves the survival of patients with extensive-disease small-cell lung cancer: a propensity score matched analysis of Surveillance, Epidemiology, and End Results database. Cancer Manag Res 2018;10:6525–35.

[9] Lin SF, Zheng YZ, Li XQ, et al. Impact of treatment modality on long-term survival of stage IA small-cell lung cancer patients: a cohort study of the U.S. SEER database. Ann Transl Med 2020;8:1292.

[10] Zhao H, Ren D, Liu H, Chen J. Comparison and discussion of the treatment guidelines for small cell lung cancer. Thorac Cancer 2018;9:769–74.

[11] Liu W, Wu J. Lung cancer with bone metastases in the United States: an analysis from the Surveillance, Epidemiologic, and End Results database. Clin Exp Metastasis 2018;35:753–61.

[12] Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 2015;16:165–72.

[13] Song Q, Shang J, Zhang C, Zhang L, Wu X. Impact of the homogeneous and heterogeneous risk factors on the incidence and survival outcome of bone metastasis in NSCLC patients. J Cancer Res Clin Oncol 2019;145:737–46.

[14] Huang Z, Hu C, Tong Y, Fan Z, Zhao C. Construction of a nomogram to predict the prognosis of non-small-cell lung cancer with brain metastases. Medicine 2020;99:e211339.

[15] Liao Y, Fan X, Wang X. Effects of different metastasis patterns, surgery and other factors on the prognosis of patients with stage IV non-small cell lung cancer: a Surveillance, Epidemiology, and End Results (SEER) linked database analysis. Oncol Lett 2019;18:581–92.

[16] Huang Z, Tong Y, Tian H, Zhao C. Establishment of a prognostic nomogram for lung adenocarcinoma with brain metastases. World Neurosurg 2020;141:e700–9.

[17] Gong L, Xu L, Yuan Z, Wang Z, Zhao L, Wang P. Clinical outcome for small cell lung cancer patients with bone metastases at the time of diagnosis. J Bone Oncol 2019;19:100265.

[18] Gu Y, Zhang J, Zhou Z, et al. Metastasis patterns and prognosis of octogenarians with NSCLC: a population-based study. Aging Dis 2020;11:82–92.

[19] Xu G, Cui P, Zhang C, et al. Racial disparities in bone metastasis patterns and targeted screening and treatment strategies in newly diagnosed lung cancer patients. Ethn Health 2020;1–14.

[20] Riihimäki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer 2014;86:78–84.

[21] Reddy SP, Dowell JE, Pan E. Predictors of prognosis of synchronous brain metastases in small-cell lung cancer patients. Clin Exp Metastasis 2020;37:531–9.

[22] Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now? a review. Transl Lung Cancer Res 2016;5:26–38.

[23] Murray N, Turrisi AT3rd. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 2006;1:270–8.

[24] Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008;26:4001–11.

[25] Nieder C, Tollali T, Yobuta R, Reigstad A, Flatoy LR, Pawinski A. Palliative thoracic radiotherapy for lung cancer: what is the impact of total radiation dose on survival? J Clin Oncol Res 2017;9:482–7.